Clinical Trials Logo

Primary CNS Lymphoma clinical trials

View clinical trials related to Primary CNS Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04464200 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Start date: July 6, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find this dose, they can test it in future participants to see if it is effective in treating their relapsed/refractory B-cell cell cancers. This study will also look at whether 19(T2)28z1xx CAR T cells work against participants' cancer.

NCT ID: NCT04443829 Active, not recruiting - Clinical trials for Primary CNS Lymphoma

Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma

CAROUSEL
Start date: March 23, 2021
Phase: Phase 1
Study type: Interventional

The CAROUSEL Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age ≥16) with relapsed/refractory Primary CNS Lymphoma. The study will evaluate the feasibility of generating the ATIMP, the safety of administering CD19CAR T-cell therapy and how effectively CD19CAR T-cells engraft, expand and persist following administration in patients with relapsed/refractory primary CNS lymphoma.

NCT ID: NCT04134117 Active, not recruiting - Clinical trials for Primary CNS Lymphoma

Tisagenlecleucel In Primary CNS Lymphoma

Start date: December 11, 2019
Phase: Phase 1
Study type: Interventional

In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. . -The name of the study intervention is tisagenlecleucel.